See Recent Shionogi-Sponsored Congress Presentations

Congresses

As part of our commitment to addressing unmet medical needs, Shionogi continues to investigate approved products and pipeline compounds. Shionogi presents its research at major congress events globally.

The content contained herein is for your information only. No reproduction, alteration, or distribution of this information is permitted. Information about investigational compounds or investigational uses of products does not imply FDA approval of these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the investigational compounds or investigational uses will receive FDA approval. Shionogi does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.

Select a congress event or filter to view available congress presentations.

You Are Viewing Presentations

AAN 2026
Edaravone

Exploratory post hoc analysis of neutrophil-to-lymphocyte ratio as a novel responsiveness biomarker for edaravone oral suspension-treated patients with amyotrophic lateral sclerosis vs untreated propensity score-matched PRO-ACT historical placebo controls

AAN 2026
Edaravone

Smartphone application-mediated, supervised, at-home telespirometry identifies statistically significant differences in erect and supine slow vital capacity and ALSFRS-R decline as a function of non-invasive ventilation treatment status in multicenter, prospective, longitudinal, observational clinical study [NCT05106569]

You Are Viewing Congress Locations